Neurocrine Biosciences (NBIX) Enterprise Value (2010 - 2026)

Neurocrine Biosciences' Enterprise Value history runs 17 years deep, the most recent figure standing at -$1.3 billion for Q1 2026.

• Quarterly Enterprise Value fell 39.5% year-over-year to -$1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.3 billion (down 39.5% YoY) and the FY2025 annual result came in at -$1.5 billion, down 37.57% from the prior year.
• Enterprise Value was -$1.3 billion for Q1 2026 at Neurocrine Biosciences, up from -$1.5 billion in the prior quarter.
• Across five years, Enterprise Value topped out at -$648.3 million in Q2 2022 and bottomed at -$1.5 billion in Q4 2025.
• A 5-year average of -$1.0 billion and a median of -$1.0 billion in 2024 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2022 — Enterprise Value climbed 26.74% — and 2023, when it sank 50.66%.
• Neurocrine Biosciences' Enterprise Value stood at -$997.1 million in 2022, then fell by 4.26% to -$1.0 billion in 2023, then slipped by 3.51% to -$1.1 billion in 2024, then tumbled by 37.57% to -$1.5 billion in 2025, then increased by 11.09% to -$1.3 billion in 2026.
• Business Quant data shows NBIX's Enterprise Value at -$1.3 billion in Q1 2026, -$1.5 billion in Q4 2025, and -$1.1 billion in Q3 2025.